Cancer Medicine

Article	Citations
Changing trends in the disease burden of esophageal cancer in China from 1990 to 2017 and its predicted level in 25 years	92
Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma	88
Enhancement of tumor lethality of ROS in photodynamic therapy	80
Disparities in telemedicine during COVID‐19	77
Global, regional and national incidence, mortality and disability‐adjusted life‐years of skin cancers and trend analysis from 1990 to 2019: An analysis of the Global Burden of Disease Study 2019	76
Prehabilitation exercise therapy for cancer: A systematic review and meta‐analysis	73
Role of tumor microenvironment in cancer progression and therapeutic strategy	73
Artificial intelligence in oncology: Path to implementation	72
Symptom clusters experienced by breast cancer patients at various treatment stages: A systematic review	72
Perspectives, fears and expectations of patients with gynaecological cancers during the COVID‐19 pandemic: A Pan‐European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe	69
Chinese and global burdens of gastric cancer from 1990 to 2019	66
Safety and Efficacy of PD‐1/PD‐L1 inhibitors combined with radiotherapy in patients with non‐small‐cell lung cancer: a systematic review and meta‐analysis	62
Protein disulphide isomerase inhibition as a potential cancer therapeutic strategy	61
The prognostic utility of pre‐treatment neutrophil‐to‐lymphocyte‐ratio (NLR) in colorectal cancer: A systematic review and meta‐analysis	57
Relationship of established risk factors with breast cancer subtypes	55
Relmacabtagene autoleucel (relma‐cel) CD19 CAR‐T therapy for adults with heavily pretreated relapsed/refractory large B‐cell lymphoma in China	53
Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019	52
Integration of comprehensive genomic profiling, tumor mutational burden, and PD‐L1 expression to identify novel biomarkers of immunotherapy in non‐small cell lung cancer	49
The effect of anticancer treatment on cancer patients with COVID‐19: A systematic review and meta‐analysis	44
Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial	44
Breastfeeding reduces the risk of breast cancer: A call for action in high‐income countries with low rates of breastfeeding	44
Esophageal cancer: trends in incidence and mortality in China from 2005 to 2015	43
Perspectives and controversies regarding the use of natural products for the treatment of lung cancer	42
Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma	42
Global, regional, and national burden and quality of care index (QCI) of thyroid cancer: A systematic analysis of the Global Burden of Disease Study 1990–2017	42

Machine learning for the prediction of bone metastasis in patients with newly diagnosed thyroid cancer	41
Examining the association among fear of COVID‐19, psychological distress, and delays in cancer care	40
Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head‐and‐neck cancer	39
Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients	38
Genetically predicted 486 blood metabolites in relation to risk of colorectal cancer: A Mendelian randomization study	38
Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer	38
Gut microbiota and risk of five common cancers: A univariable and multivariable Mendelian randomization study	38
The burden of primary liver cancer caused by specific etiologies from 1990 to 2019 at the global, regional, and national levels	37
Trends in the incidence of head and neck cancer by subsite between 1993 and 2015 in Japan	37
Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors	37
The roles of ferroptosis regulatory gene SLC7A11 in renal cell carcinoma: A multi‐omics study	37
A Body Shape Index (ABSI), hip index, and risk of cancer in the UK Biobank cohort	37
The global burden of thyroid cancer and its attributable risk factor in 195 countries and territories: A systematic analysis for the Global Burden of Disease Study	36
Contemporaneous symptom networks of multidimensional symptom experiences in cancer survivors: A network analysis	36
Sequential CD19 and BCMA‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma	35
Identification of novel subtypes based on ssGSEA in immune‐related prognostic signature for tongue squamous cell carcinoma	35
Defining comprehensive biomarker‐related testing and treatment practices for advanced non‐small‐cell lung cancer: Results of a survey of U.S. oncologists	35
Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial	34
Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer	34
Immunotherapies for hepatocellular carcinoma	34
Development and validation of MRI‐based deep learning models for prediction of microsatellite instability in rectal cancer	33
A systematic review and meta‐analysis of the prognostic role of age in oral tongue cancer	33
Marital status and survival in cancer patients: A systematic review and meta‐analysis	33
Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy‐induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomi	33
miR‐140‐3p inhibits colorectal cancer progression and its liver metastasis by targeting BCL9 and BCL2	32
A population study of screening history and diagnostic outcomes of women with invasive cervical cancer	32
The cancer patient’s perspective of COVID‐19‐induced distress—A cross‐sectional study and a longitudinal comparison of HRQOL assessed before and during the pandemic	32
Bladder cancer cell‐intrinsic PD‐L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy	32
The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively	31
Real‐world experience of carfilzomib‐associated cardiovascular adverse events: SEER‐Medicare data set analysis	31
Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database	30
Prediction of lung metastases in thyroid cancer using machine learning based on SEER database	30
Checkpoint inhibitor/interleukin‐based combination therapy of cancer	30
Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC	30
LncRNA MALAT1 accelerates non‐small cell lung cancer progression via regulating miR‐185‐5p/MDM4 axis	30
NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability	30
Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib	29
SIRT3 promotion reduces resistance to cisplatin in lung cancer by modulating the FOXO3/CDT1 axis	29
Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta‐analysis	29
Impact of early palliative care according to baseline symptom severity: Secondary analysis of a cluster‐randomized controlled trial in patients with advanced cancer	29
225Ac‐labeled CD33‐targeting antibody reverses resistance to Bcl‐2 inhibitor venetoclax in acute myeloid leukemia models	29
Novel strategies to reverse chemoresistance in colorectal cancer	29
A modifiable risk factors atlas of lung cancer: A Mendelian randomization study	29
Using deep learning to identify bladder cancers with FGFR‐activating mutations from histology images	29
Racial disparities negatively impact outcomes in early‐onset colorectal cancer independent of socioeconomic status	28
MRPL15 is a novel prognostic biomarker and therapeutic target for epithelial ovarian cancer	28
Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Dat	28
Phase II study (KAMELEON) of single‐agent T‐DM1 in patients with HER2‐positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma	28
HHLA2 deficiency inhibits non‐small cell lung cancer progression and THP‐1 macrophage M2 polarization	28
Breast cancer brain metastasis: Current evidence and future directions	28

Chimeric antigen receptor T (CAR‐T) cells: Novel cell therapy for hematological malignancies	28
Global, regional, and national burden of cancers attributable to tobacco smoking in 204 countries and territories, 1990–2019	28
Treatment patterns and survival in metastatic castration‐sensitive prostate cancer in the US Veterans Health Administration	28
Lidocaine inhibits the metastatic potential of ovarian cancer by blocking NaV1.5‐mediated EMT and FAK/Paxillin signaling pathway	27
Artificial intelligence‐assisted colonoscopy: A prospective, multicenter, randomized controlled trial of polyp detection	27
A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite‐stable metastatic colorectal cancer	27
Association of image‐defined risk factors with clinical features, histopathology, and outcomes in neuroblastoma	27
Comprehensive analysis of pan‐cancer reveals potential of ASF1B as a prognostic and immunological biomarker	27
Impact of physical exercise in advanced‐stage cancer patients: Systematic review and meta‐analysis	27
Circ‐UBAP2 functions as sponges of miR‐1205 and miR‐382 to promote glioma progression by modulating STC1 expression	27
A practical nomogram and risk stratification system predicting the cancer‐specific survival for patients with early hepatocellular carcinoma	26
Pivotal factors associated with the immunosuppressive tumor microenvironment and melanoma metastasis	26
Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature	26
Circular RNA: A promising new star for the diagnosis and treatment of colorectal cancer	26
The immune landscape during the tumorigenesis of cervical cancer	26
Validation of International Working Group response criteria in higher‐risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium	26
HELLS, a chromatin remodeler is highly expressed in pancreatic cancer and downregulation of it impairs tumor growth and sensitizes to cisplatin by reexpressing the tumor suppressor TGFBR3	26
Decreasing trends in thyroid cancer incidence in South Korea: What happened in South Korea?	26
Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma	26
EBV‐positive B‐cell lymphomas and lymphoproliferative disorders: Review from the perspective of immune escape and immunodeficiency	26
Trends in solitary plasmacytoma, extramedullary plasmacytoma, and plasma cell myeloma incidence and myeloma mortality by racial‐ethnic group, United States 2003‐2016	26
TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis	25
A novel five‐gene signature predicts overall survival of patients with hepatocellular carcinoma	25
Evaluating adipose‐derived stem cell exosomes as miRNA drug delivery systems for the treatment of bladder cancer	25
miRNA‐122‐5p in POI ovarian‐derived exosomes promotes granulosa cell apoptosis by regulating BCL9	25
Comprehensive molecular profiling broadens treatment options for breast cancer patients	25
Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer	25
Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH‐wildtype glioblastoma	25
Clathrin‐mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild‐type EGFR non‐small cell lung cancer	24
Pretreatment Glasgow prognostic score predicts survival among patients with high PD‐L1 expression administered first‐line pembrolizumab monotherapy for non‐small cell lung cancer	24
Exercise intervention decreases acute and late doxorubicin‐induced cardiotoxicity	24
Long noncoding RNA MCM3AP‐AS1 enhances cell proliferation and metastasis in colorectal cancer by regulating miR‐193a‐5p/SENP1	24
Characteristics and prognosis of synchronous multiple primary lung cancer after surgical treatment: A systematic review and meta‐analysis of current evidence	24
Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non‐small cell lung cancer	24
Identification and validation of a ferroptosis‐related gene signature for predicting survival in skin cutaneous melanoma	23
The bigger picture of shared decision making: A service design perspective using the care path of locally advanced pancreatic cancer as a case	23
Association between pre‐diagnostic serum albumin and cancer risk: Results from a prospective population‐based study	23
A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma	23
Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer	23
Demoralisation and its link with depression, psychological adjustment and suicidality among cancer patients: A network psychometrics approach	23
MiR‐362 suppresses cervical cancer progression via directly targeting BAP31 and activating TGFβ/Smad pathway	23
Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non‐small cell lung cancer	23
A real‐world data of Immune checkpoint inhibitors in solid tumors from India	23
MicroRNA‐501‐3p inhibits the proliferation of kidney cancer cells by targeting WTAP	23
Predictive role of diffusion‐weighted whole‐body MRI (DW‐MRI) imaging response according to MY‐RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined e	23
Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urot	22
The lncRNA XIST/miR‐125b‐2‐3p axis modulates cell proliferation and chemotherapeutic sensitivity via targeting Wee1 in colorectal cancer	22
Clinical outcomes of stereotactic magnetic resonance image‐guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis	22
Fat mass and obesity‐associated protein regulates tumorigenesis of arecoline‐promoted human oral carcinoma	22
Patient‐derived scaffolds as a model of colorectal cancer	22
Systematic review of neighborhood socioeconomic indices studied across the cancer control continuum	22
Indocyanine green is a sensitive adjunct in the identification and surgical management of local and metastatic hepatoblastoma	22
WGCNA identification of TLR7 as a novel diagnostic biomarker, progression and prognostic indicator, and immunotherapeutic target for stomach adenocarcinoma	22
Autophagy: A challengeable paradox in cancer treatment	22
Identification of a glycolysis‐related gene signature for survival prediction of ovarian cancer patients	22
Salivary biomarkers in breast cancer diagnosis: A systematic review and diagnostic meta‐analysis	22
Interleukin‐25: New perspective and state‐of‐the‐art in cancer prognosis and treatment approaches	22
N6‐methyladenine‐related genes affect biological behavior and the prognosis of glioma	22
Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis	22
Discovery and validation of novel biomarkers for detection of cervical cancer	21
Comparison of quality of life and cosmetic result between open and transaxillary endoscopic thyroid lobectomy for papillary thyroid microcarcinoma survivors: A single‐center prospective cohort study	21
Metabolic reprogramming of immune cells: Shaping the tumor microenvironment in hepatocellular carcinoma	21
Prevalence and predictors of peripheral neuropathy after breast cancer treatment	21
Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment	21
Post‐traumatic stress symptoms in long‐term disease‐free cancer survivors and their family caregivers	21
Efficacy of fusion imaging for immediate post‐ablation assessment of malignant liver neoplasms: A systematic review	21
Sarcopenia on preoperative chest computed tomography predicts cancer‐specific and all‐cause mortality following pneumonectomy for lung cancer: A multicenter analysis	21
Application of EfficientNet‐B0 and GRU‐based deep learning on classifying the colposcopy diagnosis of precancerous cervical lesions	21
MicroRNA‐204‐5p: A pivotal tumor suppressor	21
The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma	21
Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study	21
Systemic treatments and outcomes in CIC‐rearranged Sarcoma: A national multi‐centre clinicopathological series and literature review	20
Patterns of distant metastases in patients with clear cell renal cell carcinoma––A population‐based analysis	20
Effectiveness and safety of pyrotinib‐based therapy in patients with HER2‐positive metastatic breast cancer: A real‐world retrospective study	20
Longitudinal monitoring by next‐generation sequencing of plasma cell‐free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors	20
Periplocin inhibits the growth of pancreatic cancer by inducing apoptosis via AMPK‐mTOR signaling	20
Moxibustion for treating cancer‐related fatigue: A multicenter, assessor‐blinded, randomized controlled clinical trial	20
Establishment of patient‐derived organotypic tumor spheroid models for tumor microenvironment modeling	20
Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross‐sectional and longitudinal analysis using two large national registries	20
Prevalence and risk of psychological distress, anxiety and depression in adolescent and young adult (AYA) cancer survivors: A systematic review and meta‐analysis	20

Plasma metabolomic profile associated with fatigue in cancer patients	20
A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer	20
Extramedullary plasmacytoma: Tumor occurrence and therapeutic concepts—A follow‐up	20
Trametinib therapy for children with neurofibromatosis type 1 and life‐threatening plexiform neurofibroma or treatment‐refractory low‐grade glioma	20
Has tumor doubling time in breast cancer changed over the past 80 years? A systematic review	20
Estimated annual prevalence, medical service utilization and direct costs of lung cancer in urban China	20
Long‐term quality of life & functional outcomes after treatment of oropharyngeal cancer	20
Trust and shared decision‐making among individuals with multiple myeloma: A qualitative study	20
TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer	19
Prognostic value of IGFBP2 in various cancers: a systematic review and meta‐analysis	19
ALOX5‐5‐HETE promotes gastric cancer growth and alleviates chemotherapy toxicity via MEK/ERK activation	19
A multicenter study of clinical impact of variant of uncertain significance reclassification in breast, ovarian and colorectal cancer susceptibility genes	19
Does biomarker use in oncology improve clinical trial failure risk? A large‐scale analysis	19
The patient perspective in the era of personalized medicine: What about scanxiety?	19
Nutrition intervention is beneficial to the quality of life of patients with gastrointestinal cancer undergoing chemotherapy in Vietnam	19
Exploring the anti‐cancer potential of dietary phytochemicals for the patients with breast cancer: A comprehensive review	19
Effect of targeted therapy and immunotherapy on advanced nonsmall‐cell lung cancer outcomes in the real world	19
BACH1 promotes the progression of esophageal squamous cell carcinoma by inducing the epithelial–mesenchymal transition and angiogenesis	19
Challenges posed by COVID‐19 in cancer patients: A narrative review	19
Expansion of the quality of care index on breast cancer and its risk factors using the global burden of disease study 2019	19
Histopathological image and gene expression pattern analysis for predicting molecular features and prognosis of head and neck squamous cell carcinoma	18
Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma	18
Hepatocyte nuclear factor 1 beta: A perspective in cancer	18
Patient perspectives on chemotherapy de‐escalation in breast cancer	18
The optimal cut‐off value in fit‐based colorectal cancer screening: An observational study	18
Metabolic response as assessed by18F‐fluorodeoxyglucose positron emission tomography‐computed tomography does not predict outcome in patients with intermediate‐ or high‐risk rhabdomyosarcom	18
Characteristics and risk factors for microbial infections during cancer immune checkpoint therapy	18
Evaluating palliative opportunities in pediatric patients with leukemia and lymphoma	18
Efficacy and safety of anamorelin in patients with cancer cachexia: Post‐hoc subgroup analyses of a placebo‐controlled study	18
Older cancer patients and COVID‐19 outbreak: Practical considerations and recommendations	18
Methylation status and long‐fragment cell‐free DNA are prognostic biomarkers for gastric cancer	18
Sentinel lymph node biopsy in early stage cervical cancer: A meta‐analysis	18
Biomarkers for pancreatic cancer based on tissue and serum metabolomics analysis in a multicenter study	18
Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin	18
Immune landscape and a promising immune prognostic model associated with TP53 in early‐stage lung adenocarcinoma	17
Incidence and survival of childhood central nervous system tumors in Denmark, 1997–2019	17
Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study	17
New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validati	17
BCAT1: A risk factor in multiple cancers based on a pan‐cancer analysis	17
Associations of systemic inflammation markers with identification of pulmonary nodule and incident lung cancer in Chinese population	17
An immune‐related seven‐lncRNA signature for head and neck squamous cell carcinoma	17
Disparities in cancer prevalence, incidence, and mortality for incarcerated and formerly incarcerated patients: A scoping review	17
ITGB1 as a prognostic biomarker correlated with immune suppression in gastric cancer	17
Skeletal muscle and adipose tissue changes in the first phase of treatment of pediatric solid tumors	17
The efficacy of anti‐programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma	17
Differential immune signatures in the tumor microenvironment are associated with colon cancer racial disparities	17
Yoga for cancer survivors with chemotherapy‐induced peripheral neuropathy: Health‐related quality of life outcomes	17
The oncogenic role of the cerebral endothelial cell adhesion molecule (CERCAM) in bladder cancer cells in vitro and in vivo	17
Iron imbalance in cancer: Intersection of deficiency and overload	17
Individualized circulating tumor DNA monitoring in head and neck squamous cell carcinoma	17
Poor tumor differentiation is an independent adverse prognostic variable in patients with locally advanced oral cavity cancer––Comparison with pathological risk factors according to the NCCN guideline	17
Causal associations between gastroesophageal reflux disease and lung cancer risk: A Mendelian randomization study	17
Gastric and esophageal cancer in China 2000 to 2030: Recent trends and short‐term predictions of the future burden	17
A necroptosis‐related gene signature for predicting prognosis, immune landscape, and drug sensitivity in hepatocellular carcinoma	17
CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma	17
Integrated pan‐cancer of AURKA expression and drug sensitivity analysis reveals increased expression of AURKA is responsible for drug resistance	17
Exostosin1 as a novel prognostic and predictive biomarker for squamous cell lung carcinoma: A study based on bioinformatics analysis	17
Efficacy and safety of PD‐1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study	17
A screening assistance system for cervical cytology of squamous cell atypia based on a two‐step combined CNN algorithm with label smoothing	17
Cumulative cancer incidence and mortality after kidney transplantation in Japan: A long‐term multicenter cohort study	16
The quality of life in papillary thyroid microcarcinoma patients undergoing lobectomy or total thyroidectomy: A cross‐sectional study	16
Aspirin, metformin, and statin use on the risk of gastric cancer: A nationwide population‐based cohort study in Korea with systematic review and meta‐analysis	16
Downregulation of CYP2E1 is associated with poor prognosis and tumor progression of gliomas	16
CINSARC in high‐risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG‐STS 1001 study	16
Combination antiangiogenic tyrosine kinase inhibition and anti‐PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes	16
Association between blood pressure and BMI with bladder cancer risk and mortality in 340,000 men in three Swedish cohorts	16
Computational detection of a genome instability‐derived lncRNA signature for predicting the clinical outcome of lung adenocarcinoma	16
The prognostic role of C‐reactive protein in patients with head and neck squamous cell carcinoma: A meta‐analysis	16
Implications of estrogen and its receptors in colorectal carcinoma	16
Infectious complications of immune checkpoint inhibitors in solid organ malignancies	16
Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first‐line treatment for unresectable hepatocellular carcinoma	16
Standardization of organoid culture in cancer research	16
Evaluation of autoantibodies as predictors of treatment response and immune‐related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan‐cancer study	16
A blind randomized validated convolutional neural network for auto‐segmentation of clinical target volume in rectal cancer patients receiving neoadjuvant radiotherapy	16
Age‐specific prevalence of human papillomavirus and abnormal cytology at baseline in a diverse statewide prospective cohort of individuals undergoing cervical cancer screening in Mississippi	16
Low‐grade chronic inflammation and immune alterations in childhood and adolescent cancer survivors: A contribution to accelerated aging?	16
SphK1‐driven autophagy potentiates focal adhesion paxillin‐mediated metastasis in colorectal cancer	16
Delay in the diagnosis and treatment of breast cancer in Vietnam	16
Fermented and nonfermented soy foods and the risk of breast cancer in a Japanese population‐based cohort study	16
Acute patient‐reported outcomes in B‐cell malignancies treated with axicabtagene ciloleucel	16
Income loss after a cancer diagnosis in Germany: An analysis based on the socio‐economic panel survey	16
Neurobiology of cancer: Definition, historical overview, and clinical implications	16
Biomarkers predictive of response to pembrolizumab in head and neck cancer	16
Rapid decline in visceral adipose tissue over 1 month is associated with poor prognosis in patients with unresectable pancreatic cancer	16
Hyperthermia combined with immune checkpoint inhibitor therapy: Synergistic sensitization and clinical outcomes	16
R‐COMP versus R‐CHOP as first‐line therapy for diffuse large B‐cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group	16
Impacts of ADH1B rs1229984 and ALDH2 rs671 polymorphisms on risks of alcohol‐related disorder and cancer	16
Pharmacogenomics of cisplatin‐induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy	16
Growth and differentiation factor 15 and NF‐κB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection	15
Prognostic significance of serum inflammation indexes in different Lauren classification of gastric cancer	15
Signatures of malignant cells and novel therapeutic targets revealed by single‐cell sequencing in lung adenocarcinoma	15
Characteristics of anal canal cancer in Japan	15
Regional and racial disparity in proximal gastric cancer survival outcomes 1996–2016: Results from SEER and China National Cancer Center database	15
Efficacy and safety of anlotinib combined with PD‐1/PD‐L1 inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancer	15
Trajectories and risk factors for anxiety and depression in children and adolescents with cancer: A 1‐year follow‐up	15